| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0006 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0008 |